Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1989 Feb;75(2):252–257.

Suppression of polyclonal B cell proliferation mediated by supernatants from human myeloma bone marrow cell cultures.

D Peest 1, R Hölscher 1, R Weber 1, R Leo 1, H Deicher 1
PMCID: PMC1542115  PMID: 2784737

Abstract

For functional characterization and semi-quantitative estimation of soluble regulator factors influencing polyclonal B cell proliferation and differentiation, we established two assays. One of the assays measures enhancement or inhibition of proliferation from purified human spleen B lymphocytes, and the other one the effect of soluble factors on CESS-cell differentiation. We found no difference concerning regulator factors for B cell differentiation between bone marrow cell culture supernatants from multiple myeloma (MM) patients and from controls, whereas significantly higher suppressor activity on polyclonal B cell proliferation could be detected in the former group of supernatants. The extent of such determined suppressor activity in vitro correlated with the amount of polyclonal serum IgM of the corresponding patients. These results indicate that one or several soluble suppressor factors may be involved in immunoregulatory mechanisms responsible for the humoral immunodeficiency observed in MM patients.

Full text

PDF
252

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berman J. E., Zolla-Pazner S. Control of B cell proliferation: inhibition of responses to B cell mitogens induced by plasma cell tumors. J Immunol. 1985 May;134(5):2872–2878. [PubMed] [Google Scholar]
  2. Broder S., Humphrey R., Durm M., Blackman M., Meade B., Goldman C., Strober W., Waldmann T. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med. 1975 Oct 30;293(18):887–892. doi: 10.1056/NEJM197510302931801. [DOI] [PubMed] [Google Scholar]
  3. Chen Y. H., Heller P. Diffusible suppressor factor from splenic macrophages in murine plasmacytoma. Clin Exp Immunol. 1984 Jul;57(1):171–177. [PMC free article] [PubMed] [Google Scholar]
  4. Chen Y. H., Heller P. Suppressor activity of splenic macrophages in murine plasmacytoma (PC) is inhibited by PC specific ligands. Clin Exp Immunol. 1982 Nov;50(2):366–373. [PMC free article] [PubMed] [Google Scholar]
  5. FAHEY J. L., SCOGGINS R., UTZ J. P., SZWED C. F. INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA. Am J Med. 1963 Nov;35:698–707. doi: 10.1016/0002-9343(63)90140-2. [DOI] [PubMed] [Google Scholar]
  6. Gordon J., Aman P., Rosén A., Ernberg I., Ehlin-Henriksson B., Klein G. Capacity of B-lymphocytic lines of diverse tumor origin to produce and respond to B-cell growth factors: a progression model for B-cell lymphomagenesis. Int J Cancer. 1985 Feb 15;35(2):251–256. doi: 10.1002/ijc.2910350218. [DOI] [PubMed] [Google Scholar]
  7. Hoover R. G., Lynch R. G. Isotype-specific suppression of IgA: suppression of IgA responses in BALB/c mice by T alpha cells. J Immunol. 1983 Feb;130(2):521–523. [PubMed] [Google Scholar]
  8. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
  9. Kennard J., Zolla-Pazner S. Origin and function of suppressor macrophages in myeloma. J Immunol. 1980 Jan;124(1):268–273. [PubMed] [Google Scholar]
  10. Klein B., Jourdan M., Vazquez A., Dugas B., Bataille R. Production of growth factors by human myeloma cells. Cancer Res. 1987 Sep 15;47(18):4856–4860. [PubMed] [Google Scholar]
  11. Knapp W., Baumgartner G. Monocyte-mediated suppression of human B lymphocyte differentiation in vitro. J Immunol. 1978 Sep;121(3):1177–1183. [PubMed] [Google Scholar]
  12. Kontiainen S., Nuutinen M., Wangel A. Suppression of in vivo antibody responses by suppressor factors induced by human myeloma proteins. Acta Pathol Microbiol Immunol Scand C. 1987 Jun;95(3):101–105. doi: 10.1111/j.1699-0463.1987.tb00015.x. [DOI] [PubMed] [Google Scholar]
  13. Krakauer R. S., Strober W., Waldmann T. A. Hypogammaglobulinemia in experimental myeloma: the role of suppressor factors from mononuclear phagocytes. J Immunol. 1977 Apr;118(4):1385–1390. [PubMed] [Google Scholar]
  14. Peest D., Brunkhorst U., Schedel I., Deicher H. In vitro immunoglobulin production by peripheral blood mononuclear cells from multiple myeloma patients and patients with benign monoclonal gammopathy. Regulation by cell subsets. Scand J Immunol. 1984 Feb;19(2):149–157. doi: 10.1111/j.1365-3083.1984.tb00911.x. [DOI] [PubMed] [Google Scholar]
  15. Peest D., Holm G., Mellstedt H., Pettersson D. In vitro production of monoclonal and polyclonal immunoglobulins by peripheral blood mononuclear cells in human plasma cell myeloma. Scand J Immunol. 1982 Jun;15(6):595–603. doi: 10.1111/j.1365-3083.1982.tb00689.x. [DOI] [PubMed] [Google Scholar]
  16. Perri R. T., Oken M. M., Kay N. E. Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma. J Lab Clin Med. 1982 Apr;99(4):512–519. [PubMed] [Google Scholar]
  17. Pilarski L. M., Mant M. J., Ruether B. A., Belch A. Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients. J Clin Invest. 1984 Oct;74(4):1301–1306. doi: 10.1172/JCI111540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pruzanski W., Gidon M. S., Roy A. Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis. Clin Immunol Immunopathol. 1980 Oct;17(2):280–286. doi: 10.1016/0090-1229(80)90097-5. [DOI] [PubMed] [Google Scholar]
  19. Schwarting R., Welte K., Chiorazzi N., Ralph P., Lane C. L., Long C., Wang C. Y. Biochemical characterization and purification of human B cell stimulatory factor (BSF). Eur J Immunol. 1985 Jun;15(6):632–637. doi: 10.1002/eji.1830150619. [DOI] [PubMed] [Google Scholar]
  20. Stoll C., Schedel I., Peest D. Serum antibodies against common antigens of bacterial lipopolysaccharides in healthy adults and in patients with multiple myeloma. Infection. 1985 May-Jun;13(3):115–119. doi: 10.1007/BF01642869. [DOI] [PubMed] [Google Scholar]
  21. Twomey J. J. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med. 1973 Oct;132(4):562–565. [PubMed] [Google Scholar]
  22. Wangel A. G., Kontiainen S., Arvilommi H., Nuutinen M., Koistinen J. Suppressor factors generated from human mononuclear cells by means of purified myeloma proteins. Scand J Immunol. 1986 Mar;23(3):267–271. doi: 10.1111/j.1365-3083.1986.tb01967.x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES